TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive DeVita On Problems Of Drug Response: There May be Tw Populations Of Cells; Molecular Medicine will Change Treatment December 13, 1991
TCL Archive Advocacy Groups Form Council To Lobby For Cancer Programs To Benefit Minorities April 28, 1995
TCL Archive In Brief: New Clinical Education Program Guidelines Due; Maryland Has First Mammography Screening Law May 30, 1986
TCL Archive After Congressional Inquiry, NCI Posts Ambiguous Statement On Abortion And Breast Cancer Risk December 13, 2002
